Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Arvinas, Inc.

Market Cap 495M 432M 400M 375M 702M 46.67B 707M 4.74B 1.84B 22.98B 1.86B 1.82B 79.88B P/E 2026 *
-2.82x
P/E 2027 * -2.1x
Enterprise Value -64.03M -55.86M -51.7M -48.48M -90.76M -6.04B -91.42M -613M -238M -2.97B -240M -235M -10.34B EV / Sales 2026 *
-0.5x
EV / Sales 2027 * 3.28x
Free-Float
79.86%
Yield 2026 *
-
Yield 2027 * -
1 week+1.19%
Current month-14.59%
1 month-15.71%
3 months-29.89%
6 months-34.33%
Current year-35.33%
1 week 7.28
Extreme 7.28
8.02
1 month 6.97
Extreme 6.97
9.34
Current year 6.97
Extreme 6.97
14.51
1 year 6.06
Extreme 6.055
14.51
3 years 5.9
Extreme 5.9
53.08
5 years 5.9
Extreme 5.9
108.46
10 years 5.9
Extreme 5.9
108.46
Manager TitleAgeSince
Chief Executive Officer 47 2026-02-11
Director of Finance/CFO 56 2024-06-23
Chief Tech/Sci/R&D Officer 58 2024-06-16
Director TitleAgeSince
Chairman 66 2023-06-14
Director/Board Member 64 2018-06-30
Chairman 67 2026-02-11
Date Insider Type Main position Quantity % Market Cap.
06-16Sell

Chief Technology Officer

-2,576 0.0040%
05-20Sell

Chief Executive Officer

-2,209 0.0035%
05-10Sell

Chief Technology Officer

-11,108 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+1.19%+3.09%-73.81% 495M
+1.44%-1.25%+64.25%+114.23% 55.19B
+4.60%+3.02%+57.38%+48.98% 45.75B
-1.44%+0.39%-14.68%-17.33% 22.98B
-2.69%-2.10%-6.70%+374.02% 20.76B
+3.22%-0.84%+27.88%-20.46% 16.26B
+0.58%+1.08%+18.85%-37.32% 15.42B
-1.01%-2.30%+28.59%+174.08% 13.05B
+4.95%+11.70%+125.78%+252.19% 12.45B
+3.07%+0.14%+29.05% - 12.37B
Average +1.27%+2.83%+33.35%+90.51% 21.47B
Weighted average by Cap. +1.62%+1.49%+40.69%+100.71%

Financials

2026 *2027 *
Net sales 127M 111M 103M 96.38M 180M 12.01B 182M 1.22B 472M 5.91B 478M 468M 20.55B 68.41M 59.69M 55.24M 51.8M 96.98M 6.45B 97.68M 655M 254M 3.18B 257M 251M 11.04B
Net income -177M -154M -143M -134M -250M -16.65B -252M -1.69B -655M -8.2B -663M -648M -28.49B -254M -222M -205M -192M -360M -23.94B -362M -2.43B -942M -11.79B -953M -932M -40.98B
Net Debt -559M -488M -451M -423M -792M -52.71B -798M -5.35B -2.07B -25.96B -2.1B -2.05B -90.22B -270M -236M -218M -205M -383M -25.48B -386M -2.59B -1B -12.55B -1.01B -992M -43.62B
Logo Arvinas, Inc.
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Employees
246
Date Price Change Volume
26-06-18 7.670 $ 0.00% 957,543
26-06-17 7.670 $ +3.37% 638,616
26-06-16 7.420 $ -0.93% 519,472
26-06-15 7.490 $ -1.19% 575,600
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
7.670USD
Average target price
14.80USD
Spread / Average Target
+92.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARVN Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!